Page 1

November 5 , 2021 IMMUNOVANT Immunovant Reports Financial Results for the Quarter Ended September 30 , 2021 Company Ended the Quarter With Cash of Approximately $ 559 Million NEW YORK , Nov. 05 , 2021 ( GLOBE NEWSWIRE ) -- Immunovant , Inc. ( Nasdaq : IMVT ) , a clinical - stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases , today reported financial results for its fiscal first quarter ended September 30 , 2021. Immunovant ended the quarter with approximately $ 559 million in cash . Financial Highlights for Fiscal Second Quarter Ended September 30 , 2021 : R & D Expenses : Research and development expenses were $ 21.4 million for the three months ended September 30 , 2021 , compared to $ 12.0 million for the three months ended September 30 , 2020. The year - over - year increase primarily reflected higher contract manufacturing costs and personnel - related expenses ( including stock - based compensation ) , reflecting investment spending to support our strategic objectives as we prepare to re - initiate our clinical activities . These increases were partially offset by lower program - specific clinical trial activities due to the continued voluntary pause . G & A Expenses : General and administrative expenses were $ 16.3 million for the three months ended September 30 , 2021 , compared to $ 9.0 million for the three months ended September 30 , 2020. The year - over - year increase was primarily due to financial advisory fees , legal and other professional costs and higher personnel - related expenses ( including stock - based compensation ) . Net Loss : Net loss was $ 37.7 million ( $ 0.35 per common share ) for the three months ended September 30 , 2021 , compared to $ 20.8 million ( $ 0.25 per common share ) for the three months ended September 30 , 2020. Net loss for the three months ended September 30 , 2021 and 2020 included $ 8.4 million and $ 3.4 million , respectively , related to non - cash stock - based compensation expense . Common Stock : As of September 30 , 2021 , there were 114,998,871 shares of common stock issued and outstanding . Financial Highlights for Fiscal Six Months Ended September 30 , 2021 : R & D Expenses : Research and development expenses were $ 40.1 million for the six months ended September 30 , 2021 , compared to $ 28.9 million for the six months ended September 30 , 2020. The year - over - year increase primarily reflected higher personnel - related expenses ( including stock - based compensation ) , increases in clinical studies and clinical research and higher contract manufacturing costs , reflecting investment spending to support our strategic objectives as we prepare to re - initiate our clinical activities . These increases were partially offset by lower program - specific clinical trial activities due to the continued voluntary pause .